Browse by author
Lookup NU author(s): Professor John O'Brien
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The NINCDS-ADRDA and the DSM-IV-TR criteria for Alzheimer's disease (AD) are the prevailing diagnostic standards in research; however, they have now fallen behind the unprecedented growth of scientific knowledge. Distinctive and reliable biomarkers of AD are now available through structural MRI, molecular neuroimaging with PET, and cerebrospinal fluid analyses. This progress provides the impetus for our proposal of revised diagnostic criteria for AD. Our framework was developed to capture both the earliest stages, before full-blown dementia, as well as the full spectrum of the illness. These new criteria are centred on a clinical core of early and significant episodic memory impairment. They stipulate that there must also be at least one or more abnormal biomarkers among structural neuroimaging with MRI, molecular neuroimaging with PET, and cerebrospinal fluid analysis of amyloid 0 or tau proteins. The timeliness of these criteria is highlighted by the many drugs in development that are directed at changing pathogenesis, particularly at the production and clearance of amyloid 0 as well as at the hyperphosphorylation state of tau. Validation studies in existing and prospective cohorts are needed to advance these criteria and optimise their sensitivity, specificity, and accuracy.
Author(s): Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delocourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Solloway S, Stern Y, Visser PJ, Scheltens P
Publication type: Review
Publication status: Published
Journal: Lancet Neurology
Year: 2007
Volume: 6
Issue: 8
Pages: 734-746
ISSN (print): 1474-4422
ISSN (electronic): 1474-4465
URL: http://dx.doi.org/10.1016/S1474-4422(07)70178-3
DOI: 10.1016/S1474-4422(07)70178-3
